Printer Friendly

Business briefs.

COLUMN: BUSINESS BRIEFS

TELEGRAM & GAZETTE

Bloomberg Index

Central Massachusetts

-8.49

120.46

Volume: 60,371,478

Up: 4

Down: 18

Unchanged: 7

Gainer: Valpey-Fisher Corp. $4.25 +$.20 (volume of 21,600 shares)

Decliner: Waters Corp. $42.75 -$5.56 (volume of 1.46 million shares)

Local

T&G d.b.a. debuts

WORCESTER - The Telegram & Gazette announced the launch of d.b.a., a monthly advertising supplement magazine for business professionals and entrepreneurs in Central Massachusetts.

Formerly the Buzz, d.b.a. has been redesigned to provide business information and networking opportunities, as well as event listings.

The premiere issue was published yesterday. In the future it will be published the first Wednesday of each month and distributed free by mail to businesses throughout Worcester County. It will be available at selected locations.

"Professionals who are experts in their field have agreed to serve as regular contributors," said d.b.a. Editor Rod Lee.

The initials d.b.a. stand for "doing business as," a term commonly used by small businesses to identify their trade names. d.b.a. content is also available at www.telegram.com/dba.

ASC in S. Korea

DEVENS - American Superconductor Corp. announced that it has licensed two of its proprietary wind turbine designs to South Korea-based Hyundai Heavy Industries Co. Ltd., the world's largest shipbuilder, a provider of turnkey power plants and offshore projects, and a major global supplier of high voltage electrical equipment.

Lanza co-chair

WORCESTER - Advanced Cell Technology Inc. announced that Dr. Robert Lanza, the company's chief scientific officer, and Dr. Tao Cheng of the Chinese Academy of Medical Sciences, are conference co-chairs of the International Forum on Stem Cells, being held today through Saturday in Tianjin, China.

The conference is organized by the Chinese Academy of Medical Sciences and the National Science Foundation of China.

Genzyme in study

CAMBRIDGE - Genzyme Corp. announced that the company has begun enrollment in a world-wide post-marketing clinical trial evaluating the effectiveness and safety of treating pediatric male patients with mild Fabry disease symptoms with a low-dose regimen of Fabrazyme. Data from the study may support supplemental submissions to regulatory agencies seeking additional dosing options that facilitate early treatment for Fabry disease.

Genzyme has operations in Westboro.

Job Fair slated

The Workforce Central Career Center and Massachusetts Division of Career Services will hold a Veterans Job Fair from 10 a.m. to 2 p.m. on Nov. 14, at the Auburn Elks Lodge, 754 Southbridge St.

For more information, visit www.workforcecentralma.org.
COPYRIGHT 2008 Worcester Telegram & Gazette
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:BUSINESS
Publication:Telegram & Gazette (Worcester, MA)
Date:Oct 16, 2008
Words:418
Previous Article:PRESS BOX.
Next Article:BRIEFS.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |